TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 616038045

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0mg
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5mg
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Center-involving DME
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combined center + non-center involving DME
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Persistent DME
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: SRF presence
Number of subjects: 119
Study: 32045734

Group type: EXPERIMENTAL
Intervention: Guided self-help exercise program (flexibility, range-of-motion and lymphedema exercises and self-care education program)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (self-care education program)
Number of subjects: 92
Study: 35051321

Group type: EXPERIMENTAL
Intervention: Resin composite group (Filtek Z350 XT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer group (RMGI) (Vitremer Tricure)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no DME)
Number of subjects: 30
Study: 35021200

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 6632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6632
Study: 32037149

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin 200 mg/kg/day for 8 weeks
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin
Number of subjects: 414
Study: 33558347

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 1084
Study: 33060432

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) ketamine 0.5 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral ketamine 1 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 45
Study: 36271428

Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic care including spinal manipulation, education, exercise, self-management advice, and myofascial therapies over 8 weeks, twice weekly sessions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic care
Number of subjects: 20
Study: 33615628

Group type: EXPERIMENTAL
Intervention: TAS0313 (9 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: TAS0313 (27 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: TAS0313 (9 mg and 27 mg)
Number of subjects: 17
Study: 35120861

Group type: EXPERIMENTAL
Intervention: Tactile, kinesthetic and oral stimulation (T + K + OS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oral stimulation (OS)
Number of subjects: 42
Study: 34024541

Group type: EXPERIMENTAL
Intervention: Dual‐Energy X‐Ray Absorptiometry (DXA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Single CT slice at L3-level
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combination of three CT slices (L2, L3, L4)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Anthropometric measurements
Number of subjects: 66
Study: 34953290

Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Biomedical-focused neck/back school (control)
Number of subjects: 120
Study: 34537926

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 836

Group type: COMPARATOR
Intervention: ESA
Number of subjects: 836
Study: 36450426

Group type: EXPERIMENTAL
Intervention: Practice nurse‐led preventive health check, a mobile application and telephone coaching
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 215
Study: 33983124

Group type: EXPERIMENTAL
Intervention: NoteAid intervention (n=89)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: NoteAid intervention (n=100 from AMT)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (n=85 from LGH)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (n=100 from AMT)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Community hospital participants
Number of subjects: 174
Study: 33397432

Group type: EXPERIMENTAL
Intervention: PVP-I nasal irrigation at 0.4%
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: PVP-I nasal irrigation at 0.5%
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: PVP-I nasal irrigation at 0.6%
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: PVP-I nasal spray at 0.5%
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: PVP-I nasal spray at 0.6%
Number of subjects: 189

Group type: COMPARATOR
Intervention: Distilled water through nasal irrigation (placebo)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Distilled water through nasal spray (placebo)
Number of subjects: 189
Study: 35830988

Group type: EXPERIMENTAL
Intervention: Low-dose low-molecular-weight-heparin (LMWH) therapy
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: High-dose low-molecular-weight-heparin (LMWH) therapy
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: High-dose low-molecular-weight-heparin (LMWH) with aspirin
Number of subjects: 164
Study: 33538643

Group type: EXPERIMENTAL
Intervention: Previsit phone call from an orthopedic surgeon
Number of subjects: 122

Group type: COMPARATOR
Intervention: No previsit phone call (control group)
Number of subjects: 122
Study: 35503305

Group type: EXPERIMENTAL
Intervention: SBIRT Intervention for Trauma Patients (SITP) - a 15-minute session with elements of cognitive behavioral therapy techniques
Number of subjects: 46

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 46
Study: 33671968

Group type: EXPERIMENTAL
Intervention: Probiotics stimulation (34 patients)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (35 patients)
Number of subjects: 69
Study: 34294494

Group type: EXPERIMENTAL
Intervention: 12-week nurse-led health coaching programme
Number of subjects: 140

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 140
Study: 33892832

Group type: EXPERIMENTAL
Intervention: Fluoride plus hydroxyapatite (Remin Pro®; RP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride plus casein phosphopeptide‐amorphous calcium phosphate fluoride (Mi Paste Plus®; MPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colgate Total®; CT (Control)
Number of subjects: 0
Study: 34791348

Group type: EXPERIMENTAL
Intervention: BMI (kg/m2)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Fat mass index (FMI: kg/m2)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Lean mass index (LMI; kg/m2)
Number of subjects: 304
Study: 32325161

Group type: EXPERIMENTAL
Intervention: Veterans with MS who died by suicide
Number of subjects: 426

Group type: COMPARATOR
Intervention: Randomly selected nonsuicide MS controls
Number of subjects: 426
Study: 35680456

Group type: EXPERIMENTAL
Intervention: Electrodiagnostic tests (EDx) recommended by surgeons
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Comfort level of surgeons offering carpal tunnel release (CTR) without EDx
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Surgeons ordering EDx for patient scenarios
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Factors associated with lower likelihood of EDx
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Factors associated with greater surgeon comfort offering CTR without EDx
Number of subjects: 91
Study: 32921503

Group type: EXPERIMENTAL
Intervention: HP-HMB supplementation (2 servings/day for up to 90 days)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: HP-HMB supplementation
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 32199490

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34734674

Group type: EXPERIMENTAL
Intervention: High-intensity physical education (HIPE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined HIPE and LIPE (PLUS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity physical education (LIPE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard physical education lessons (CTRL)
Number of subjects: 120
Study: 35154365

Group type: EXPERIMENTAL
Intervention: Conservative oxygenation (SpO2 88–92%)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care (control – SpO2 ≥96%)
Number of subjects: 34
Study: 33068617

Group type: EXPERIMENTAL
Intervention: Higher Ocular Surface Disease Index (OSDI) symptom scores
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Longitudinal increases (worsening) in OSDI scores
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Worse corneal staining and tear break‐up time
Number of subjects: 535
Study: 35748760

Group type: EXPERIMENTAL
Intervention: The Daily Mile (TDM) - a daily one mile outdoor run/walk performed at a self‐selected pace during school hours
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: The Daily Mile (TDM)
Number of subjects: 550
Study: 34727088

Group type: EXPERIMENTAL
Intervention: Self-help intervention (n = 123)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Waitlist control (n = 141)
Number of subjects: 264
Study: 32584005

Group type: EXPERIMENTAL
Intervention: Direct stenting (Group I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stenting after balloon pre-dilatation (Group II)
Number of subjects: 100
Study: 35546449

Group type: EXPERIMENTAL
Intervention: HDV-insulin lispro with a 10% decrease in BaI dose
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: HDV-insulin lispro with a 40% decrease in BaI dose
Number of subjects: 52
Study: 34343678

Group type: EXPERIMENTAL
Intervention: Knee Image Digital Analysis (KIDA)
Number of subjects: 103
Study: 35903320

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 196

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 196
Study: 33048394

Group type: EXPERIMENTAL
Intervention: Screening attendance (at least twice)
Number of subjects: 31867

Group type: COMPARATOR
Intervention: Single screening
Number of subjects: 31867

Group type: EXPERIMENTAL
Intervention: Repeated screening
Number of subjects: 31867

Group type: EXPERIMENTAL
Intervention: Number of screens attended
Number of subjects: 31867

Group type: COMPARATOR
Intervention: Control arm (non-attenders)
Number of subjects: 31867

Group type: EXPERIMENTAL
Intervention: Intermediate-risk and high-risk cases
Number of subjects: 31867
Study: 33461775

Group type: EXPERIMENTAL
Intervention: Mathematical formula defining horizontal cervical tooth geometry for prefabricated healing abutments.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cone beam computed tomography (CBCT) measurements of tooth geometry.
Number of subjects: 54
Study: 33139136

Group type: EXPERIMENTAL
Intervention: aQIV
Number of subjects: 2208

Group type: COMPARATOR
Intervention: QIV
Number of subjects: 2208
Study: 34715000

Group type: EXPERIMENTAL
Intervention: Long-acting injectable antipsychotics (LAI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral atypical antipsychotics (OAA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both LAI and OAA
Number of subjects: 60
Study: 34183032

Group type: EXPERIMENTAL
Intervention: Best RMSSD (Root Mean Square of the Successive Differences)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Good Stress Balance (SB)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Subgroup analysis among participants working regular daytime hours (n = 216)
Number of subjects: 252
Study: 34651528

Group type: EXPERIMENTAL
Intervention: WeChat-assisted health education and preoperative care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leaflet group (control)
Number of subjects: 0
Study: 34015555

Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Number of subjects: 265
Study: 32333524

Group type: EXPERIMENTAL
Intervention: Hypoxic ambulation (HAMB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normoxic bed rest (NBR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hypoxic bed rest (HBR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normoxic bed rest (NBR) and Hypoxic bed rest (HBR)
Number of subjects: 12
Study: 36207675

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed protein formula with added Lacticaseibacillus rhamnosus GG (PHF-LGG)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Marketed partially hydrolyzed cow's milk-based infant formula (PHF)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both formulas (PHF and PHF-LGG)
Number of subjects: 71
Study: 33786649

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZI) 500 mg/day for 3 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (AZI + SRP and placebo + SRP)
Number of subjects: 40
Study: 32891794

Group type: EXPERIMENTAL
Intervention: 3D-printed model and associated intervention including didactic instruction, multimedia content, and FNP practice
Number of subjects: 24
Study: 34330456

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (2000 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34118498

Group type: EXPERIMENTAL
Intervention: IVY intervention (vaccine education and quality improvement program)
Number of subjects: 4041
Study: 34106794

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32167864

Group type: EXPERIMENTAL
Intervention: Tumor deposits positive patients
Number of subjects: 1942

Group type: COMPARATOR
Intervention: Tumor deposits negative patients
Number of subjects: 1942

Group type: EXPERIMENTAL
Intervention: Multivariable analysis including TDs
Number of subjects: 1942
Study: 36145164

Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both diets (LF and Med)
Number of subjects: 0
Study: 34407695

Group type: EXPERIMENTAL
Intervention: Sachet water (46% consumption); bottled water (100%, n=2); chlorine-based disinfectants for water treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: POC water samples
Number of subjects: 100
Study: 32894248

Group type: EXPERIMENTAL
Intervention: Psychological interventions (specific interventions not detailed)
Number of subjects: 9
Study: 35246219

Group type: EXPERIMENTAL
Intervention: Personalized telephone-based weight loss intervention plus health education
Number of subjects: 220

Group type: COMPARATOR
Intervention: Health education alone
Number of subjects: 220
Study: 33522950

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 33559648

Group type: EXPERIMENTAL
Intervention: Air pollution exposure (measured by particulate matter PM2.5 and PM10)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Skin prick testing and measurement of volatile organic compounds in exhaled breath
Number of subjects: 276
Study: 32147075

Group type: EXPERIMENTAL
Intervention: Curcuminoids (500 mg plus 5 mg piperine per day for 8 weeks)
Number of subjects: 55
Study: 36201761

Group type: EXPERIMENTAL
Intervention: HRV biofeedback (HRV‐BF), 4 sessions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Autogenic training (AT), 4 sessions
Number of subjects: 50
Study: 34235821

Group type: EXPERIMENTAL
Intervention: Valvular heart disease trials
Number of subjects: 9071

Group type: COMPARATOR
Intervention: Coronary artery disease trials
Number of subjects: 9071

Group type: COMPARATOR
Intervention: Stroke trials
Number of subjects: 9071

Group type: COMPARATOR
Intervention: Atrial fibrillation trials
Number of subjects: 9071

Group type: COMPARATOR
Intervention: Surgical procedures
Number of subjects: 9071

Group type: COMPARATOR
Intervention: Drugs
Number of subjects: 9071

Group type: COMPARATOR
Intervention: Secondary prevention
Number of subjects: 9071

Group type: COMPARATOR
Intervention: Primary prevention
Number of subjects: 9071

Group type: COMPARATOR
Intervention: Tertiary prevention
Number of subjects: 9071

Group type: COMPARATOR
Intervention: Age groups ≤50 years old
Number of subjects: 9071

Group type: COMPARATOR
Intervention: Age groups 56-60 years old
Number of subjects: 9071
Study: 32436902

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids 500 mg (EPA/DHA 180/120 mg), BD daily for 1 month
Number of subjects: 90

Group type: COMPARATOR
Intervention: scaling and root planing only
Number of subjects: 90
Study: 35524839

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 48389

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 48389

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 48389

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 48389

Group type: EXPERIMENTAL
Intervention: NOACs (nonvitamin K antagonist oral anticoagulants)
Number of subjects: 48389
Study: 33258688

Group type: EXPERIMENTAL
Intervention: Remote risk-based monitoring
Number of subjects: 11

Group type: COMPARATOR
Intervention: On-site monitoring with 100% source data verification
Number of subjects: 11

Group type: COMPARATOR
Intervention: Data review by data managers
Number of subjects: 11
Study: 35281417

Group type: EXPERIMENTAL
Intervention: SILS+1
Number of subjects: 117

Group type: COMPARATOR
Intervention: CLS
Number of subjects: 117
Study: 35447066

Group type: EXPERIMENTAL
Intervention: Tick Control System (TCS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Met52 fungal spray
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TCS and Met52 used together
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study: 32366155

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: M2
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sorafenib or M2
Number of subjects: 74
Study: 36253611

Group type: EXPERIMENTAL
Intervention: Anti-tau monoclonal antibody gosuranemab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34454786

Group type: COMPARATOR
Intervention: Ro‐VLP vaccine (21 μg) in adults
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ro‐VLP vaccine (7 μg or 21 μg) in toddlers
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ro‐VLP vaccine (2.5 μg, 7 μg or 21 μg) in infants
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral Rotarix (2 doses) in infants
Number of subjects: 70
Study: 35908553

Group type: EXPERIMENTAL
Intervention: Structured leadership and management training, facilitating subregional collaboration, and routine data feedback to mid-level managers.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard practice (control group).
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Structured leadership and management training, facilitating subregional collaboration, and routine data feedback to mid-level managers (excluding Q3-2019).
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard practice (control group, excluding Q3-2019).
Number of subjects: 82
Study: 33528749

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index (CCI 5)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Venous and/or perineural invasion
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Perineural invasion
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Incomplete resection
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Postoperative mortality rate
Number of subjects: 308
Study: 32270474

Group type: EXPERIMENTAL
Intervention: 30 mL ropivacaine 0.2% bilaterally and an elastomeric pump containing 0.2% ropivacaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: 30 mL saline bilaterally and an elastomeric pump containing saline
Number of subjects: 24
Study: 32744473

Group type: EXPERIMENTAL
Intervention: Gender training intervention
Number of subjects: 0
Study: 33008432

Group type: EXPERIMENTAL
Intervention: Motor Imagery practice combined with routine physical therapy (MIp)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group receiving physical therapy alone (CON)
Number of subjects: 26
Study: 35820247

Group type: EXPERIMENTAL
Intervention: Request
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Offer
Number of subjects: 97

Group type: COMPARATOR
Intervention: Telling
Number of subjects: 97
Study: 33356403

Group type: EXPERIMENTAL
Intervention: Ultrasound renal denervation (RDN)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 122
Study: 34404275

Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Number of subjects: 438

Group type: COMPARATOR
Intervention: Nonalcoholic beverage (no-alcohol control or placebo)
Number of subjects: 438
Study: 34512759

Group type: EXPERIMENTAL
Intervention: Pomegranate peel extract mouthwash
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 60
Study: 35351144

Group type: EXPERIMENTAL
Intervention: Inulin (16 g/day) with dietary advice for 3 months
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Inulin with increased physical activity
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) with dietary advice for 3 months
Number of subjects: 106
Study: 33924761

Group type: EXPERIMENTAL
Intervention: W. cibaria CMU tablets administered once daily for 8 weeks before bedtime
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo administered once daily for 8 weeks before bedtime
Number of subjects: 68
Study: 34390436

Group type: EXPERIMENTAL
Intervention: Pedometer use (goal of 10,000 steps/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pedometer use
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no pedometer)
Number of subjects: 38
Study: 35297360

Group type: EXPERIMENTAL
Intervention: Children of mothers who gained the most gestational weight
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Children with the highest birth weight, body length and head circumference
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Children of relatively younger mothers
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Parents of preschoolers in the high adiposity category
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Boys with the highest adiposity
Number of subjects: 1112
Study: 34217356

Group type: EXPERIMENTAL
Intervention: New amino acid-based formula (AAF)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 32665367

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (Palforzia)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palforzia
Number of subjects: 0